Nov 2026· Cancer Letters· pp.
218934
· 0 citations· 76 references
Medicine
TL;DR
A novel combinational therapeutic strategy utilizing a sodium-glucose co-transporter-2 (SGLT2) inhibitor canagliflozin and a covalent KRASG12C inhibitor adagrasib to selectively target LKB1-KRASG12C co-mutated NSCLC is investigated.
Abstract
In recent years, significant progress has been made in developing targeted therapy for non-small cell lung cancer (NSCLC). However, these therapies are only applicable to specific NSCLC groups with corresponding gene mutations. Therefore, developing novel targeted therapies to benefit more patients remains an important task. Our prior work demonstrated that LKB1-mutant NSCLC cells are highly susceptible to cell death induced by glucose starvation. In this study, we investigated a novel combinational therapeutic strategy utilizing a sodium-glucose co-transporter-2 (SGLT2) inhibitor canagliflozin and a covalent KRASG12C inhibitor adagrasib, two clinically approved therapeutics, to selectively target LKB1-KRASG12C co-mutated NSCLC. First, we verified the co-occurrence of LKB1 and KRAS mutations in clinical NSCLC cohorts. Second, compared to other SGLT2 inhibitors, canagliflozin induced higher cytotoxicity in LKB1-mutant cells, and SGLT2 knockdown partially attenuated this effect. Mechanistically, the high susceptibility to canagliflozin was associated with impaired activation of AMP-activated protein kinase (AMPK). Furthermore, canagliflozin suppressed mammalian target of rapamycin (mTOR) activity and robustly inhibited cell growth in LKB1-mutant models in vitro. Third, adagrasib exhibited selective cytotoxicity in KRASG12C-mutated NSCLC. Finally, the combination of canagliflozin and adagrasib synergistically reduced cell viability in LKB1-KRASG12C co-mutated H23 and H2122 cells in vitro. Importantly, canagliflozin attenuated the adaptive MAPK signaling rebound induced by adagrasib in vitro. The therapeutic potential of this combination was confirmed in an H2122 nude mouse xenograft model in vivo. Collectively, our findings demonstrate that a combination of canagliflozin and adagrasib suppresses LKB1-KRASG12C co-mutated NSCLC, laying a solid preclinical foundation for developing a new therapeutic strategy for this group of NSCLC.
SUNRAY-02 is a 2-part global, placebo-controlled phase III study recruiting patients with stage II-III KRAS G12C-mutant NSCLC following definitive therapy, addressing a critical treatment gap in KRAS G12C-mutant early-stage NSCLC.
J. Chaft, J. Lee, Suresh Senan et al.· Future Oncology· 0 citations
BACKGROUND
MET and angiogenic pathways are activated in EGFR-mutant non-small-cell lung cancer (NSCLC) upon resistance to tyrosine-kinase inhibitors (TKIs). Amivantamab, an EGFR and MET bispecific antibody, is approved in combination with chemotherapy for EGFR-mutant NSCLC post-osimertinib progression based on results...
R. Soo, Sanjay Popat, U. Dafni et al.· The Lancet Respiratory Medic...· 0 citations
KRAS biology, therapeutic advances, mechanisms of resistance, and emerging strategies that are reshaping the treatment landscape of KRAS-mutant NSCLC are comprehensively summarized.
E. Garbo, P. Scaparone, H. J. Hoe et al.· The Journal of the National...· 0 citations
Background The treatment of KRAS G12C-mutant non-small cell lung cancer (NSCLC) has become a dominant field of ongoing translational research. Still, the effect of the first KRAS G12C inhibitor, sotorasib, or next-generation inhibitors, such as fulzerasib, in KRAS-mutant NSCLC patients is short-lived. Although the obje...
A. Giménez-Capitán, D. Olmo-González, E. Martínez-Pérez et al.· Annals of Translational Medi...· 0 citations
BACKGROUND
Osimertinib is a third-generation EGFR tyrosine kinase inhibitor that has become a mainstay treatment for EGFR-mutant non-small cell lung cancer (NSCLC). However, acquired resistance develops in most patients and ultimately compromises durable clinical benefit. Therefore, effective combination strategies to...
Recent clinical advances using RAS-targeted small-molecule inhibitors, including daraxonrasib, a RAS(ON) multi-selective, noncovalent, tri-complex inhibitor, has shown promising responses but are limited in durability for pancreatic ductal adenocarcinoma (PDAC). Preclinical studies indicate that RAS inhibition ca...
Zi-Rui Zhu, Benjamin C. Barrett, Aadi Bhattacharya et al.· Cancer Research· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.